Back to Newsroom
Back to Newsroom

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Enochian Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Friday, 01 July 2022 01:20 PM

The Schall Law Firm

Topic:
Lawsuits

LOS ANGELES, CA / ACCESSWIRE / July 1, 2022 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enochian Biosciences, Inc. ("Enochian Biosciences" or "the Company") (NASDAQ:ENOB) for violations of the securities laws.

The Schall Law Firm, Friday, July 1, 2022, Press release picture

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The DOJ announced the arrest of Enochian Biosciences co-founder and inventor Serhat Gumrukçu on May 25, 2022, during trading hours. Gumrukçu faces charges in a murder-for-hire conspiracy. Based on this news, shares of Enochian Biosciences plummeted by 37% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.
310-301-3335
[email protected]
www.schallfirm.com

SOURCE: The Schall Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom

Contact Us Today


If you have questions or want to learn more about our products, our team’s here to help!

Share by: